ABSTRACT: The purpose of this study was to compare the expression profiles of drugmetabolizing enzymes in the intestine of mouse, rat and human. Total RNA was isolated from the duodenum and the mRNA expression was measured using Affymetrix GeneChip oligonucleotide arrays. Detected genes from the intestine of mouse, rat and human were ca. 60% of 22690 sequences, 40% of 8739 and 47% of 12559, respectively. Total genes of metabolizing enzymes subjected in this study were 95, 33 and 68 genes in mouse, rat and human, respectively. Of phase I enzymes, the mouse exhibited abundant gene expressions for Cyp3a25, Cyp4v3, Cyp2d26, followed by Cyp2b20, Cyp2c65 and Cyp4f14, whereas, the rat showed higher expression profiles of Cyp3a9, Cyp2b19, Cyp4f1, Cyp17a1, Cyp2d18, Cyp27a1 and Cyp4f6. However, the highly expressed P450 enzymes were CYP3A4, CYP3A5, CYP4F3, CYP2C18, CYP2C9, CYP2D6, CYP3A7, CYP11B1 and CYP2B6 in the human. For phase II enzymes, glucuronosyltransferase Ugt1a6, glutathione S-transferases Gstp1, Gstm3 and Gsta2, sulfotransferase Sult1b1 and acyltransferase Dgat1 were highly expressed in the mouse. The rat revealed predominant expression of glucuronosyltransferases Ugt1a1 and Ugt1a7, sulfotransferase Sult1b1, acetyltransferase Dlat and acyltransferase Dgat1. On the other hand, in human, glucuronosyltransferases UGT2B15 and UGT2B17, glutathione S-transferases MGST3, GSTP1, GSTA2 and GSTM4, sulfotransferases ST1A3 and SULT1A2, acetyltransferases SAT1 and CRAT, and acyltransferase AGPAT2 were dominantly detected. Therefore, current data indicated substantial interspecies differences in the pattern of intestinal gene expression both for P450 enzymes and phase II drug-metabolizing enzymes. This genomic database is expected to improve our understanding of interspecies variations in estimating intestinal prehepatic clearance of oral drugs.
Introduction
Recent advances in genomic technology have facilitated the rapid and simultaneous determination of global profiles for thousands of genes in tissue samples directly associated with the pharmacokinetics [1] [2] [3] [4] [5] . The completion of the DNA sequencing of human, mouse and rat genomes and knowledge of cross-species gene homologies enables studies of differential gene expression in animal models [6] . Recent targeting of specific tissue genes, such as intestinal transporters or enzymes, has shown a potential to greatly enhance our understanding of pharmacokinetics including bioavailability and metabolic clearance for oral drug molecules [7] [8] [9] [10] [11] [12] . It is now *Correspondence to: Department of Veterinary Pharmacology and Toxicology, Konkuk University, Seoul 143-701, Republic of Korea. E-mail: hshin@konkuk.ac.kr accepted that the drug absorption process from the intestine is highly associated with the functional gene expression of intestinal transporters and metabolizing enzymes [7, 13] .
Many drugs are chemically altered in the body by various reactions of metabolizing enzymes. The key human enzyme subfamilies include CYP1A, CYP2A, CYP2B, CYP2C, CYP2E and CYP3A. It has been also generally understood that the major metabolizing enzymes are CYP3A4, CYP2D6, CYP2C8/9 and CYP1A2 in human. Each enzyme subfamily possesses specific selectivity toward substrate drugs. CYP3A4 shows mostly wide spectra for the metabolism of numerous drugs [14, 15] . CYP2D6 metabolizes amoxapine, chloropromazine, and codeine, and CYP2C8/9 metabolizes phenytoin, ketamine, paclitaxel, rifampin and various sulfonamides. Although the enzymes are predominantly found in the liver, the intestinal enzymes also deserve a special mechanism for modulating drug bioavailability (the main contributor of prehepatic clearance of drugs) [11] . However, little is known about the interspecies differences in the distribution pattern of individual isoforms and functions at the level of mRNA expression for the intestinal metabolizing enzymes. Therefore, the genomic comparison of intestinal enzymes among some species is very valuable for interspecies prediction of drug bioavailability and animal scaling for first-pass metabolism capacity. This study provides a comparative transcriptional database for intestinal metabolizing enzymes between model rodent animals and human.
Materials and Methods

Materials
TRIzol reagent and superscript Choice System for cDNA synthesis kit were purchased from Invitrogen (Carlsbad, CA). The BioArray high-yield RNA transcript labeling kit was purchased from Enzo Biochem (New York, NY). The RNeasy kit was obtained from Qiagen (Valencia, CA). GeneChips including MG 430A 2.0 for mouse, RG U34A for rat and HG U95A for human were purchased from Affymetrix (Santa Clara, CA). The GeneChip hybridization and scanning for RG U34A and HG U95A assays were performed at the Genomic Information Support Facility at Michigan State University (East Lansing, MI), and those for MG 430A 2.0 were carried out at the Seoulin Molecular Biology Technique Center (Seoul, Korea). Human biopsy samples were taken from the duodenum with an endoscope as described earlier [7, 16] .
Animals
Male ICR mice (32-40 g) were obtained from Orient BioCo. (Seoul, Korea) and housed in a controlled animal room of Konkuk University, Seoul, Korea. The mice were fed solid pellets with water ad libitum. Male SD rats (250-300 g) were purchased from Charles River laboratories (Wilmington, MA) and kept at the animal facility of the University of Michigan. The rat diets were purchased from TestDiet Inc (Richmond, IN).
RNA isolation
The human duodenal samples were prepared from healthy male and female volunteers (21-45 years of age, n 5 10) as described earlier [16] . All mucosal tissues of the rat (n 5 8) and mouse duodenum (n 5 6) were immediately scraped with a glass slide, transferred to a new frozen vial and dipped into liquid nitrogen. A total of 100 mg of tissue was added to 1 ml TRIzol reagent, homogenized with a tissue razor at maximum speed for 20 s Â 3 times or with a mortar on ice. The homogenate was transferred to a new tube and then 200 ml chloroform was added to the TRIzol mixture. After being centrifuged at 12500 rpm for 15 min at 41C, the aqueous phase was transferred to a new tube, and the RNA was precipitated with 500 ml of isopropanol, and washed with 80% ethanol. The RNA pellet was resuspended in 30-50 ml of DNase/RNase-free water, and the concentration was measured at 260 nm. The absorbance ratio at wavelength 260/280 nm should be at least greater than 1.6. The RNA was further purified with an RNease Mini kit (Qiagen, Valencia, CA) according to the manufacturer's manual. The concentration of the purified RNA was measured at 260 nm. The absorbance ratio at 260/280 nm of the purified RNA should be 1.7-1.8. The purified RNA was checked in agarose/formaldehyde gel for quality before further cRNA labeling. Five mg of purified RNA was mixed with RNA loading buffer and heated at 751C for 15 min. After cooling down on ice for 5 min, the RNA was loaded on 1% agarose/formaldehyde gel in 1 X MOPS buffer. The gel was run at 80-100 V for 50 min and two sharp 18S and 28S bands should be visible under UV.
Microarray assay
Probe synthesis from total RNA samples, hybridization, detection and scanning were performed according to the standard protocols from Affymetrix, Inc. (Santa Clara, CA). In the rat and human, single stranded cDNA was transcribed from 5-8 mg total RNA using T7-(dT) 24 oligomer primer, the primer was annealed at 701C for 10 min, and then Superscript II reverse transcriptase was used for reverse transcription at 421C for 1 h. The double stranded cDNA was synthesized from first-strand cDNA using DNA ligase, DNA polymerase I and T4 DNA polymerase at 161C for 2 h using SuperScript Choice System for cDNA synthesis kit (Gibco/BRL, Grand Island, NY, USA). The reaction was stopped by adding 10 ml of 0.5 M EDTA. The double strand cDNA was then cleaned by phenol/chloroform extraction with phase-locking gel and ethanol precipitation in the presence of 1 mg of glycogen. Biotin-labeled cRNA was synthesized from the double strand cDNA using T7 RNA polymerasecatalysed in vitro transcription in the presence of biotin-labeled NTP (BioArray high yield RNA transcription labeling kit, Enzo Biochem, New York, NY) at 371C for 5 h, and the labeled cRNA was purified using RNease mini kit (Qiagen). The concentration of labeled cRNA was measured at 260 nm. A total of 20 mg of labeled cRNA was fragmented at 951C. Biotinlabeled cRNA was heated at 991C for 5 min in hybridization cocktail including hybridization control (Bio B, C, D and Cre) and hybridized with GeneChip s (Affymetrix, Santa Clara, CA) at 421C for 16 h. The GeneChip s was then washed with non-stringent wash buffer at 501C and stained with streptavidin phycoerythrin (SAPE) solution. After washing at 251C, the GeneChip s was scanned with a laser scanner (Affymetrix). In mouse, cDNA was synthesised using the One-Cycle cDNA Synthesis Kit (Affymetrix, Santa Clara, CA). Single stranded cDNA was synthesised using Superscript II reverse transcriptase and T7-oligo(dT) primers at 421C for 1 h. Double stranded cDNA was obtained by using DNA ligase, DNA polymerase I and RNase H at 161C for 2 h, followed by T4 DNA polymerase at 161C for 5 min. After clean up with a Sample Cleanup Module (Affymetrix, Santa Clara, CA), ds-cDNA was used for in vitro transcription (IVT). cDNA was transcribed using the GeneChip IVT Labeling Kit (Affymetrix, Santa Clara, CA), in the presence of biotinlabelled CTP and UTP. After clean up with a Sample Cleanup Molule (Affymetrix, Santa Clara, CA), the biotin-labelled IVT-RNA was fragmented. Fragmented cRNA was hybridized to the mouse gene chip MG 430A 2.0 at 451C for 16 h according to the manufacturer's instructions. After hybridization, the arrays were washed in a GeneChip Fluidics Station 450 with a nonstringent wash buffer at 251C followed by a stringent wash buffer at 501C. After washing, the arrays were stained with a streptavidin-phycoerythrin complex. Afterwards, they were processed according to the procedure described above for rat and human array. The duodenal mRNA expression profile obtained for SLC15A1 from microarray data analyses was validated using semiquantitative RT-PCR. The RT-PCR assay was performed as described previously [16] . SLC15A1 mRNA expression in the individual biopsies determined by RT-PCR exhibited a pattern similar to that observed with the microarray data (r 2 5 0.89).
Data analysis
Official symbols and gene names were used in accordance with the symbol and name lists approved by HUGO (Human Genome Organization) Gene Nomenclature Committee (http:// www.genenames.org). Data analysis was performed using different software packages including Microarray Suite (Affymetrix, Santa Clara, CA) and GeneSpring 6.2 (Silicon Genetics, Redwood City, CA). Numeric data were extracted from DAT images and normalized using the Microarray Suite. Gene function analysis was performed using the gene ontology-mining tool of NetAffx, which is based on the Gene Ontology database (http:// www.geneontology.org). GeneSpring also uses data found publicly in genomics databases to build gene ontologies based on annotation information. For the present GeneChip probe array study, the data for each gene represent data from 11-20 probe pairs each approximately 25 bp in length. For each probe pair, one probe is a perfect match while the other has a single mismatch at nucleotide 13. The mismatch probe works as an internal control to evaluate the cross hybridizations between closely related target sequences. The overall target-specific intensity was obtained by the difference between the intensity of perfect match and the mismatch probes. GeneChip Operating Software (GCOS, Affymetrix, CA) was used to determine the absolute analysis metrics (Detection, Detection p-value) using the scanned probe array data and compared between the different treatment group signals to generate the Change, Change p-value, and Signal log ratio (fold change). For normalization, data from each expression array were scaled, so that the overall fluorescence intensity across each chip was equivalent (average target intensity set at 500). The 'Selected Probe Sets' method was applied using the normalization control probe sets. Equivalency for arrays being compared was assessed based on the scaling/normalization factors calculated by the 'Selected Probe Sets' (GCOS, Affymetrix, CA). The one-sided Wilcoxon's signed rank test was employed to generate the detection pvalue. If the overall intensity of perfect match was much larger than that of mismatch, the detection pvalue would be small. The probe set would be regarded as present if the p-value was less than 0.04 and if the p-value was higher than 0.06, the probe set would be regarded as absent. The detection threshold was set as the 'present' call output from GCOS (po0.05). Two sets of algorithms were generated and they were used to generate change significance and change quantity metrics for every probe set. The change algorithm generated a Change p-value and an associated fold-change value. The second algorithm gave a quantitative estimate of the change in gene expression in the form of Signal Log Ratio. The level of gene expression was regarded as increased if its Change p-value was less than 0.0025 and the gene expression would be considered to be decreased if its Change p-value was greater than 0.9975. Only relative changes equal or greater than 2-fold level of expression were considered. For a given gene transcript in any chip-to-chip comparison, GCOS generates a 'change call' parameter ('increase' or 'decrease') based on a consideration of signal specificity as well as intensity.
Results
Expression profiles of 22690 gene sequences in mouse intestine, 8739 in rat and 12559 in human were analysed. Detected genes were ca. 60%, 40% and 47% from mouse, rat and human intestine, respectively. This paper focused on the expression of metabolizing enzymes as critical factors modulating prehepatic clearance of many oral substrates. As shown in Table 1 , the total numbers of metabolizing enzymes detected were 95, 33 and 68 genes in mouse, rat and human intestine, respectively. Relatively higher intensities of gene expression were observed in glucuronosyltransferases and acyltransferases. Figure 1 shows the expression of P450s. Several types of Cyp3a including Cyp3a25, Cyp3a9 and Cyp3a4 were dominantly expressed in mouse, rat and human. Expression intensities The expressions of other P450s were minor or negligible. Of UDP-glucuronsyltransferases (UGT), higher expression levels were observed in Ugt1a6 (mouse), Ugt1a1 and Ugt1a7 (rat) and UGT2B15 and UGT2B17 of human compared with the other UGTs ( Figure 2 ). As shown in Figure 3 , expression intensity of glutathione S-transferases was in the order Gstp1 4 Gstm3 4 Gsta2 4 Mgst3 4 Mgst1 4 Gsto1 4 Gstm1 4 Mgst2 in mouse, and MGST3 4 GSTP1 4 GSTA2 4 GSTM4 4 MGST2 4 GSTM1 in human. Figure 4 shows that sulfotransferases had a similar gene expression pattern between mouse and rat. Sult1b1 was distinctly expressed both in mouse and rat, but not detected in human. Human revealed a dramatically higher intensity of ST1A3 and SULT1A2 expression. Of the acetyltransferases ( Figure 5 ), Acat1 and Sat1 were highly expressed in mouse, Dlat in rat, and SAT1 and CART in human. Figure 6 shows the acyltransferase expression levels in these species. Rat showed a very high expression intensity of Dgat1, and mouse expressed Dgat1 and Acaa2 at high levels. In human, AGPAT2 and AGPAT1 were found at higher levels.
Discussion
It was widely recognized that there were marked inter-or intraspecies differences in distribution and functions of each metabolizing enzyme class including cytochrome P450s and transferases. However, since these studies focused on the hepatic metabolism [17] , there has been very poor information regarding other tissues such as intestine. Therefore, it is necessary to develop P450 and transferase-based differential screening systems that may able to predict the risk and pharmacological responses of xenobiotics between animals and humans. Recently, these screening systems are being accomplished by use of genomic techniques. Molecular probes are being used to screen the levels of gene expression of drug-related enzymes in an effort to determine whether expression of certain P450 forms or transferases is associated with increased drug discovery and risk assessment [1, 2] . Cytochrome P450s, a class of phase I metabolizing enzymes, are dominantly expressed in liver and intestine to regulate metabolism and oral bioavailability, and these enzymes have shown a very wide range of substrate specificities [18, 19] . For this reason, examining the differences in the expression levels of these enzymes among some species may provide insight into the differences in PK and drug bioavailability properties. Up to now, there are more than 71 characterized cytochrome P450 genes by HUGO. These enzymes are responsible for the metabolism (at least partial metabolism) of approximately 75% of all drugs, with the CYP3A subfamily being responsible for nearly half of this activity [20, 21] . Because of their wide substrate spectrums and potential for numerous drug-drug interactions in both preclinical and clinical studies, these subfamilies CYP1A, CYP2A, CYP2B, CYP2D, CYP2E and CYP3A are considered as key enzymes [21] [22] [23] . In our study, mice showed primary expression of Cyp3a25, Cyp4v3 and Cyp2d26, and rats revealed higher Figure 3 . Comparative gene expression for various glutathione S-transferases in the intestine of mice, rats and humans (n 4 6). Expression levels were measured by the intensity of hybridization signal using GeneChip array. (GSTA2-4, glutathione Stransferase, alpha 2-4; GSTK1, glutathione S-transferase, kappa 1; GSTM1-6, glutathione S-transferase, mu 1-6; GSTO1, glutathione S-transferase, omega 1; GSTP1, glutathione S-transferase, pi 2; GSTT1-3, glutathione S-transferase, theta 1-3; GSTZ1, glutathione transferase, zeta 1 (maleylacetoacetate isomerase); MGST1-3, microsomal glutathione S-transferase 1-3) transcription of Cyp3a9, Cyp2b19, Cyp4f1 and Cyp17a1. On the other hand, humans have dominantly expressed CYP3A4, CYP3A5, CYP4F3 and CYP2C subfamilies. Expression intensities of the other minor P450 genes were also considerably different among these species. Significant expression of Cyp3a25 in mouse intestine has been also reported by earlier investigators [24, 25] , though an identification study of intestinal P450s has not been well described in mouse intestine compared with rat and human. It is well known that the CYP3A4 is a predominant P450 enzyme in human intestine, and Cyp3a9 in rat intestine [26, 27] . Wacher et al. [28] reported that CYP3A4 in human intestine plays a significant role in the first-pass metabolism of 50-70% of marketed drugs. Zierold et al. [29] and Xue et al. [30] reported that the human CYP3A4 is thought to be the homolog of the rat Cyp3a9, though the two enzymes are not identical because of four different amino acids in the substrate recognition site. Human CYP3A4 reveals higher homology of DNA sequence with rat Cyp3a9 (81%) than that of mouse Cyp3a25 (76%). These data might indicate that there are extensive interspecies variations in the preference of substrate structure recognition, though few members of CYP3A subfamily, including Cyp3a25, Cyp3a9 and CYP3A4, are expressed as the principal gene in these species. Therefore, this result may partially explain 'why the oral first-pass metabolism of many substrates differs in these species'.
Probably the most common conjugation reaction is the synthesis of glucuronic acid derivatives (glucuronides). Aliphatic alcohols, phenols, carboxylic acids, mercaptans, primary and secondary aliphatic amines, and carbamates are converted to their beta-glucuronide derivatives by UDP-glucuronosyltransferase (UGT). In our study, higher expression levels were observed in Ugt1a6 of mouse, Ugt1a1 and Ugt1a7 of rat, and UGT2B15 and UGT2B17 of human when compared with other glucuronosyltransferases. Glutathione S-transferases are ubiquitous multifunctional proteins involved in the detoxification of endogenous and xenobiotic compounds using either glutathione conjugation or glutathione peroxidase activity [31, 32] . The major roles of GSTs are the metabolism of electrophilic carcinogens and alkene and arene oxides [33] . The data show interspecies variability for the expression pattern of glutathione S-transferases. Expression intensity was high in Sgtp1, Gstm3, Gsta2, Mgst3, Mgst1 and Gsto1 in mouse, and MGST3, GSTP1, GSTA2, GSTM4 and MGST2 in human. However, in rats, the enzyme Gstm5 was merely observed at the lower level. Sulfotransferase (SULT) catalyses the transfer of a sulfate group to the hydroxyl group of drug compounds [34] . Sult1b1 was distinctly expressed in both mouse and rat, but not detected in humans. On the other hand, human revealed a dramatically higher intensity of ST1A3 and SULT1A2 expression. It can be summarized that sulfotransferases have a similar gene expression pattern between mouse and rat, but not human. Acetylation of drug compounds is catalysed in human and animals by various types of acetyltransferases such as MYST histone acetyltransferases (MYSTs), N-acetyltransferases (NATs) and spermidine/spermine N1-acetyltransferases (SATs). The data have shown a variety of gene expression profiles for acetyltransferases depending on the species. Acat1 and Sat1 were highly expressed in mouse, Dlat in rat, and SAT1 and CART in human in which SAT1 expression level was 3-4 fold higher than CART. Several types of xenobiotic carboxylic acids including aromatic, heteroaromatic, arylacetic, cinnamic and aryloxyacetic are conjugated with a variety of endogenous amino acids including glycine, glutamine and taurine, prior to excretion in mammals [35] . It was observed that the acyltransferase expression levels are extensively different in mouse, rat and human. Rat showed a very high expression intensity of Dgat, and mouse expressed Dgat1 and Acaa2 at high levels. However, in human, AGPAT2 and AGPAT1 were found as the primary enzyme genes compared with other acyltransferases.
The potential role of intestinal enzymes on drug first-pass metabolism has become increasingly recognized. Although animal models do not provide direct information that can be extrapolated to humans, drug metabolism studies will all benefit from the selection of animal models species that closely approximates human metabolism. Since it is very difficult technically to assay the expression of whole enzymes at proteomic levels, it is readily accepted that the gene expression studies using microarray technology is an essential tool for predicting functional expression of intestinal proteins. It is still arguable that the transcriptional profile may not be consistent with functional protein levels. Nevertheless, several recent investigations have revealed positive correlation between mRNA expression and regulation of functional proteins [7, [36] [37] [38] [39] [40] . Berggren et al. [39] reported that mRNA level of CYP3A4 was significantly correlated with its protein levels in small intestine. Overall, the data reveal that rodent animals and humans have a variety of different transcriptional profiles for metabolizing enzymes in the small intestine. To our knowledge, there has been no report directly describing interspecies difference in intestinal expression of metabolism enzymes at genomic levels. Therefore, this transcriptional data can lead to more effective use of animal models in oral drug development and application to human.
